ReviewDigital health
Digital health technologies in frontotemporal dementia: A scoping review.
Review in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Digital health technologies are increasingly used to assess cognition and behavior in neurodegenerative diseases. While such tools have shown promise in Alzheimer's disease, including the preclinical stages, their use in frontotemporal dementia (FTD) remains underexplored. This scoping review provides an overview of the current literature on digital health technologies in FTD. Methods: We conducted a literature search according to the PRISMA-ScR guidelines and included 62 studies investigating digital health technologies in individuals with FTD. Results: The identified technologies included eye tracking paradigms, smartphone- and tablet-based cognitive assessments, and passive monitoring approaches such as wearable sensors and mobile applications. Most studies reported that these technologies could distinguish individuals with FTD from healthy controls or other dementia syndromes. However, many studies were experimental or feasibility-focused, and systematic evaluation of psychometric properties remains limited. Conclusion: In order to move the field forward, we argue that an in-depth investigation of the relationships between digital health technologies, classical pen-and-paper assessments of cognitive and behavioral functioning, and other biomarkers is necessary to establish clinical validity. Other important aspects to address in future research include the use of diverse cohorts and studying longitudinal effects. In our view, these next steps are crucial to advance digital health technologies toward implementation in clinical practice and clinical trials for FTD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.